Why must the measles-rubella vaccine be administered at 8 months?

Oct 30, 2024 Source: Cainiu Health
Dr. Zhou Xiaofeng
Introduction
Under normal circumstances, the measles vaccine must be administered at 8 months of age, primarily due to factors such as immune system maturity, the optimal vaccination window, reducing the risk of infection, vaccine safety, and immunodeficiency status. Parents are advised to take their infants to the hospital promptly for the required vaccinations to ensure their child's health. After vaccination, parents should carefully monitor their infant's condition.

Measles-rubella (MR) combined attenuated live vaccine is commonly referred to as the "ma feng" vaccine. Generally, the reason why infants must receive the measles-rubella combined attenuated live vaccine at 8 months of age is influenced by several factors, including immune system maturity, optimal vaccination timing, reduction of infection risk, vaccine safety, and immune deficiency status. Parents are advised to promptly take their infants to the hospital for necessary vaccinations to ensure their child's health. The detailed analysis is as follows:

1. Immune System Maturity

After birth, an infant’s immune system gradually develops and matures. By 8 months of age, the immune system has developed sufficient capacity to respond to external pathogens. Administering the measles-rubella combined attenuated live vaccine at this stage can more effectively stimulate the immune system to produce antibodies, thereby establishing immunological memory against measles and rubella.

2. Optimal Vaccination Window

Eight months of age represents one of the optimal time windows for administering the measles-rubella combined attenuated live vaccine. Vaccination at this time ensures maximum protective efficacy. Vaccinating too early may result in reduced effectiveness due to interference from maternal antibodies, while delaying vaccination increases the risk of measles infection in unimmunized children.

3. Reduction of Infection Risk

Diseases such as measles and rubella are highly contagious and pose serious health threats to infants. Timely administration of the measles-rubella combined attenuated live vaccine can significantly reduce the risk of infection, protecting infants from these diseases.

4. Vaccine Safety

The measles-rubella combined attenuated live vaccine is approved for use only after rigorous evaluation of its safety and efficacy. Administration at 8 months of age ensures optimal safety in infants. Furthermore, strict quality control standards are followed throughout the vaccine’s production, storage, and transportation, further ensuring its safety.

5. Immune Deficiency Status

Infants with certain immunodeficiency conditions or those receiving immunosuppressive treatments may have impaired immune responses to the measles virus, making them more susceptible to infection and prone to more severe illness. Timely vaccination helps prevent such diseases and protects infant health.

After vaccination, parents are advised to closely monitor their infant’s condition to identify and manage any potential adverse reactions following immunization.

Related Articles

View All